Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15317977 | 1.00 | ANPEP (0.46) | ANPEPERAP2THRBMEN1KMT2A | |
| SCHEMBL22778666 | 1.00 | ANPEP (0.46) | ANPEPERAP2THRBMEN1KMT2A | |
| SCHEMBL20363524 | 1.00 | ANPEP (0.46) | ANPEPERAP2THRBMEN1KMT2A | |
| SCHEMBL15317976 | 0.95 | — | — | |
| SCHEMBL2898816 | 0.95 | — | — | |
| SCHEMBL19903768 | 0.95 | — | — | |
| SCHEMBL18780235 | 0.85 | — | — | |
| SCHEMBL22757590 | 0.85 | — | — | |
| SCHEMBL13766461 | 0.85 | — | — | |
| SCHEMBL4224636 | 0.82 | ANPEP (0.43) | ANPEPERAP2THRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623398-B1 | RESIN COMPOSITION COMPRISING A MODIFIED BLOCK COPOLYMER AND METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER | ASAHI CHEMICAL IND (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-110603273-B | Modified block copolymer, method for producing modified block copolymer, and resin composition | 旭化成株式会社 | 2022-10-14 | — | — | CN | disclosed |
| CN-114773400-A | Rhodium complex, preparation method, intermediate and application thereof | 中国科学院上海有机化学研究所 | 2022-07-22 | — | — | CN | disclosed |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11124593-B2 | Modified block copolymer, method for producing modified block copolymer, and resin composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-09-21 | — | — | US | disclosed |
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | AbbVie Deutschland GmbH & Co. KG (DE) | 2021-01-21 | — | — | US | disclosed |
| US-20200199282-A1 | Modified Block Copolymer, Method for Producing Modified Block Copolymer, and Resin Composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-06-25 | — | — | US | disclosed |
| EP-3623398-A1 | MODIFIED BLOCK COPOLYMER, METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER, AND RESIN COMPOSITION | Asahi Kasei Kabushiki Kaisha (JP) | 2020-03-18 | — | — | EP | disclosed |
| CN-110603273-A | Modified block copolymer, method for producing modified block copolymer, and resin composition | 旭化成株式会社 | 2019-12-20 | — | — | CN | disclosed |
| US-10167303-B2 | Iridium organometallic complex containing a substituted dibenzo[f,h]quinoxaline and an electronic device having an emitting layer containing the iridium complex | UDC IRELAND LIMITED (IE) | 2019-01-01 | — | — | US | disclosed |
| US-8269046-B2 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY, LLC (US) | 2012-09-18 | — | — | US | disclosed |
| EP-1631633-B1 | CYCLIC BISAMIDES USEFUL IN FORMULATING INKS FOR PHASE-CHANGE PRINTING | ARIZONA CHEM (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20100064933-A1 | Cyclic Bisamides Useful in Formulating Inks for Phase-Change Printing | ARIZONA CHEMICAL COMPANY LLC | 2010-03-18 | — | — | US | disclosed |
| EP-1829877-A1 | BICYCLIC PYRROLE DERIVATIVES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| US-20060128992-A1 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY | 2006-06-15 | — | — | US | disclosed |
| EP-1631633-A2 | CYCLIC BISAMIDES USEFUL IN FORMULATING INKS FOR PHASE-CHANGE PRINTING | Arizona Chemical Company (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6960248-B2 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| WO-2004106442-A2 | CYCLIC BISAMIDES USEFUL IN FORMULATING INKS FOR PHASE-CHANGE PRINTING | ARIZONA CHEMICAL COMPANY (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040231555-A1 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167303-B2 | Iridium organometallic complex containing a substituted dibenzo[f,h]quinoxaline and an electronic device having an emitting layer containing the iridium complex | NDUFS5, DDT, NDUFV2 | ANPEP 4484/4885ERAP2 4529/4885THRB 4360/4885 |
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | LIPA, ALG1, CEL | ANPEP 1127/4885ERAP2 4101/4885THRB 4775/4885 |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | LIPA, ALG1, CEL | ANPEP 1127/4885ERAP2 4101/4885THRB 4775/4885 |
| US-20070082908-A1 | Bicycle pyrazole derivative | DPP4, DPP7, DPP3 | ANPEP 953/4885ERAP2 1389/4885THRB 1192/4885 |
| US-20060128992-A1 | Cyclic bisamides useful in formulating inks for phase-change printing | FHIT, DDC, MNAT1 | ANPEP 2496/4885ERAP2 3259/4885THRB 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.